This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baron, J. L., Madri, J. A., Ruddle, N. H., Hashim, G., and Janeway, C. A. Jr. 1993. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177:57–68.
Bayless, K. J., Meininger, G. A., Scholtz, J. M., and Davis, G. E. 1998. Osteopontin is a ligand for the α4β1 integrin. J. Cell Sci. 111:1165–1174.
Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta S. L, Havrdova E, Hutchinson M, Kappos L, Miller DH, O’Connor P. W, Phillips J. T, Polman C. H, Radue E. W, Rudick R. A, Stuart W. H, Lublin F. D, Wajgt A, Weinstock-Guttman B, Wynn D. R, Lynn F, Panzara M. A; AFFIRM and SENTINEL Investigators. 2007. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 69:1391–1401.
Chabas, D., Baranzini, S. E., Mitchell, D., et al. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731–1735.
Chan, P. Y. and Aruffo, A. 1993. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J. Biol. Chem. 268:24655–24664.
Davis, L. S., Oppenheimer-Marks, N., Bednarczyk, J. L., McIntyre, B. W., and Lipsky, P. E. 1990. Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J. Immunol. 145:785–793.
DeStefano, N., Matthews, P. M., Fu, L., Narayanan, S., Stanley, J., Francis, G. S., Antel, J. P., and Arnold, D. L. 1998. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469–1477.
Elices, M. J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M. E., and Lobb, R. R. 1990. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:577–584.
ffrench-Constant, C. 1994. Pathogenesis of multiple sclerosis. Lancet 343:271–275.
Freund, M., von Wussow, P., Diedrich, H., Eisert, R., Link, H., Wilke, H., Buchholz, F., Leblanc, S., Fonatsch, C., Deicher, H., and Poliwada, H. 1989. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br. J. Haematol. 72:350–356.
Giannelli, G., Antonelli, G., Fera, G., Del Vecchio, S., Riva, E., Broccia, C., Schiraldi, O., and Dianzani, F. 1994. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy for chronic hepatitis C. Clin. Exp. Immunol. 97:4–9.
Kleinschmidt-DeMasters, B. K. and Tyler, K. L. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353:369–374.
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., and Pelletier, D. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353:375–381.
Lobb, R. R. and Hemler, M. E. 1994. The pathophysiologic role of alpha 4 integrins in vivo. J. Clin. Invest. 94:1722–1728.
Lublin, F. D. 2005. Multiple sclerosis trial designs for the 21st century: building on recent lessons. J. Neurol. 252(Suppl. 5):46–53.
Meager, A. 1994. Human antibodies to insulin in diabetes. J. Interferon Res. 14:181–182.
Miller, D. H., Khan, O. A., Sheremata, W. A,. Blumhardt, L. D., Rice, G. P., Libonati, M. A., Willmer-Hulme, A.J., Dalton, C. M., Miszkiel, K. A., and O’ Connor, P. W. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:15–23.
Mould, A. P., Wheldon, L. A., Komoriya, A., Wayner, E. A., Yamada, K. M., and Humphries, M. J. 1990. Affinity chromatographic isolation of the melanoma adhesion receptor for the IIICS region of fibronectin and its identification as the integrin alpha 4 beta 1. J. Biol. Chem. 265:4020–4024.
O’Regan, A. W., Chupp, G. L., Lowry, J.A., Goetschkes M., Mulligan, N., and Berman, J. S. 1999. Osteopontin is associated wit T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J. Immunol. 162: 1024–1031.
Polman, C. H., O’Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., and Sandrock, A. W. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899–910.
Rudick, R. A., Stuart, W. H., Calabresi, P.A., Confavreux, C., Galetta, S. L., Radue, E. W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., and Sandrock, A. W. 2006. Natalizumab plus interferon beta-1 for relapsing multiple sclerosis. N. Engl. J. Med. 354:911–923.
Rudick, R. A. and Sandrock A. 2004. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurotherapeutics 4:571–580.
Schellekens, H. 2002 Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. 1:457–462.
Sheremata, W. A., Vollmer, T. L., Stone, L. A., Willmer-Hulme, A. J., and Koller, M. A. 1999. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52:1072–1074.
Tysabri Product Information. 2006. Biogen Idec Inc, Cambridge, MA.
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., and Rutgeerts, P. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. 353:362–368.
Weinshenker, B. G., Bass, B., Rice, G. P. A., Noseworthy, J., Carriere, W., Baskerville, J., and Ebers, G. C. 1989. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:133–146.
Wolinsky, J. S. 2003. Rational therapy for relapsing multiple sclerosis. Lancet Neurol. 2:271–272.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Subramanyam, M. (2008). Case Study: Immunogenicity of Natalizumab. In: Weert, M.v., Møller, E.H. (eds) Immunogenicity of Biopharmaceuticals. Biotechnology: Pharmaceutical Aspects, vol VIII. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75841-1_10
Download citation
DOI: https://doi.org/10.1007/978-0-387-75841-1_10
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-75840-4
Online ISBN: 978-0-387-75841-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
